EGFR+ Lung Cancer
Latest News
Atezolizumab Shows OS Benefit Over Chemo in Frontline Advanced PD-L1-High NSCLC
By Lisa Astor
Latest Videos
More News
Bemcentinib, a first-in-class AXL inhibitor, in combination with the PD-1 inhibitor pembrolizumab showed activity in patients with immunotherapy-naive advanced non–small cell lung cancer, according to findings from the phase II study presented at the 2019 World Conference on Lung Cancer.
A statistically significant improvement in overall survival was demonstrated with durvalumab, a PD-L1 inhibitor, combined with chemotherapy in patients with previously untreated extensive-stage small cell lung cancer, according to findings from the phase III CASPIAN trial, presented at the 2019 World Conference on Lung Cancer.
The FDA has granted a fast track designation to AMG 510 for the treatment of patients with previously treated metastatic non–small cell lung cancer harboring a <em>KRAS </em>G12C mutation.
In a recent analysis published in <em>JAMA</em>, data were evaluated from a collection of clinical trials and analyzed for important takeaways in the testing and treatment of patients with non–small cell lung cancer. The authors stress the importance of molecular testing in patients with NSCLC as more targeted therapies become available. <br />
The FDA has granted capmatinib a breakthrough therapy designation as a first-line treatment for patients with <em>MET </em>exon 14 skipping mutation–positive non–small cell lung cancer.
Corey J. Langer, MD, detailed the best courses of treatment for a patient with non–small cell lung cancer to a group of physicians during a recent Targeted Oncology live case-based peer perspectives discussion.
Sarah B. Goldberg, MD, MPH, discusses the role of clinical trials in patients with lung cancer who have molecularly altered tumors, such as <em>EGFR</em>, <em>ALK</em>, <em>BRAF</em>,<em>ROS1, </em>or other alterations. These patients typically consider either targeted therapy or immunotherapy treatment options.
The review period has been extended by the FDA for a supplemental biologics license application for atezolizumab as a frontline treatment for patients with metastatic nonsquamous non–small cell lung cancer who do not have <em>EGFR</em> or <em>ALK</em> aberrations, in combination with carboplatin and nab-paclitaxel.
Findings from a phase II study in patients with small cell lung cancer suggested tumor immune phenotypes can be predictive of response to immune checkpoint blockade. Responses to the combination of durvalumab plus olaparib were observed in all patients where tumors had an inflamed phenotype.
Lowell L. Hart, MD, FACP, scientific director of clinical research, Florida Cancer Specialists & Research Institute, and associate professor of medicine, Wake Forest University School of Medicine, discusses the effect of CDK4/6 inhibitor, trilaciclib on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan. Hart presented the phase II results from the blinded, multicenter study during the 2019 ASCO Annual Meeting.
The addition of carboplatin and pemetrexed to therapy with gefitinib in patients with non–small cell lung cancer and an <em>EGFR</em>-sensitizing mutation had a statistically significant effect on progression-free survival and overall survival and represents a new therapy option for these patients.
A 61-Year-Old Man With ALK-Rearranged NSCLC
During the <em>20th Annual </em>International Lung Cancer Congress, <em>Targeted Oncology</em> spoke with another Lung-MAP investigator, Fred R. Hirsch, MD, PhD, about the status and importance of the trial and new recommendations for molecular testing and liquid biopsies working their way into practice in the lung cancer field.
The combination of durvalumab and tremelimumab did not meet its primary overall survival endpoint compared with platinum-based chemotherapy in patients with previously untreated stage IV non–small cell lung cancer and a high tumor mutational burden, according to final OS results from the phase III NEPTUNE trial.
Twenty to 30 years ago, delivering a diagnosis of lung cancer to a patient was a difficult conversation to have for many oncologists. But that has given way to greater optimism today, according to Mark A. Socinski, MD.
The FDA has approved entrectinib for the treatment of adult patients with <em>ROS1</em>-positive metastatic non–small cell lung cancer. An accelerated approval was also granted to entrectinib for the treatment of adult and adolescent patients with solid tumors harboring an <em>NTRK </em>gene fusion and who have no alternative, effective therapies available.
Heather A. Wakelee, MD, discusses recent research investigating antiangiogenic agents and checkpoint inhibitors in the frontline for patients with <em>EGFR</em>-positive non—small cell lung cancer. The most promising data were demonstrated in the phase III IMpower150 trial.
Although chemotherapy remains the standard treatment for small cell lung cancer in first- and second-line settings, notable progress in immunotherapies have recently taken place, begging the question of how these agents will be optimized in this tumor type.